Drug search by name

Onasemnogene Abeparvovcec Infusion and Cardiac toxicity

Result of checking the interaction of drug Onasemnogene Abeparvovcec Infusion and disease Cardiac toxicity for safety when used together.

Check result:

Onasemnogene Abeparvovcec Infusion <> Cardiac toxicity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

In clinical trials, transient increases in cardiac troponin-I levels (up to 0.176 µg/L) were observed following onasemnogene abeparvovec-xioi infusion. The clinical importance of these findings is not known; however, cardiac toxicity was observed in animal studies. Care should be exercised in patients at risk. It is recommended to monitor troponin-I before infusion and weekly for the first month, and then monthly for the second and third months until troponin-I level returns to baseline as appropriate.

Onasemnogene Abeparvovcec Infusion

Generic Name: onasemnogene abeparvovec

Brand Name: Zolgensma, Zolgensma

Synonyms: Onasemnogene abeparvovec (Zolgensma), Onasemnogene Abeparvovec

What is Onasemnogene Abeparvovcec Infusion?